AI Drug Discovery Target potential partners and licensing opportunities with Aria Pharmaceuticals’ AI-driven small molecule discovery platform, focusing on accelerating preclinical programs in oncology, ophthalmology, immunology & inflammatory diseases, and metabolic disorders.

Strategic Partnerships Explore collaboration or co-development deals with larger biopharma as Aria collaborates with industry players (e.g., SK Biopharmaceuticals) to expand disease programs and leverage AI to de-risk early discovery.

Clinical Readiness Position Aria as a candidate for jointPhD-level R&D outsourcing or CRO-style engagements to advance preclinical assets, leveraging their recent leadership hires in R&D and nonclinical/chemistry to accelerate timelines.

Funding & SBIRs Identify opportunities to assist Aria in securing additional non-dilutive funding or Phase I/II SBIR grants, highlighting their prior NIH/NCI SBIR award experience to support new programs in pancreatic cancer or related areas.

Value Prop Differentiation Emphasize competitive advantages of AI-driven discovery, rapid disease area expansion capabilities, and cost/time-to-value benefits to prospective partners seeking faster preclinical candidate generation and de-risked pipelines.